SCHEDULE: Vanguard Group Maintains Significant Stake in Arrowhead Pharmaceuticals

The Vanguard Group has filed an updated Schedule 13G, reporting a continued beneficial ownership of 11.24% in Arrowhead Pharmaceuticals Inc.

Summary

• The Vanguard Group reported beneficial ownership of 15,525,072 shares of Arrowhead Pharmaceuticals Inc. Common Stock.
• This aggregate amount represents 11.24% of the class of securities.
• Vanguard holds sole dispositive power over 15,243,118 shares and shared dispositive power over 281,954 shares.
• Vanguard holds shared voting power over 142,962 shares and no sole voting power.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing is a factual report of beneficial ownership by a large institutional investor. It indicates a stable, significant holding, which can be interpreted as a neutral to slightly positive signal of confidence in the company's long-term prospects by a major fund manager.

Future Outlook

NA

Industry Context

This filing reflects a major institutional investor's continued significant stake in a biotechnology company, which is common for large asset managers like Vanguard that manage broad index funds and actively managed portfolios across various industries, including pharmaceuticals.

Stakeholder Impact

• Shareholders: The continued significant ownership by a major institutional investor like Vanguard may provide a degree of stability and confidence to other shareholders, indicating a long-term investment perspective.

Key Dates

Keywords

Arrowhead Pharmaceuticals, Vanguard Group, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Pharmaceuticals, Biotechnology